The Indian Patent Office has rejected a patent application for the BPaL regimen, a groundbreaking treatment for ...

Despite a $2.2 billion setback due to failed drug trials, Novartis raises its profit forecast for the year, highlighting ...

The CDSCO has raised a public alert regarding a counterfeit batch of the liver medication Defitelio, prompting patients to ...

Despite a 30% cap on trade margins for non-scheduled cancer drugs, prices for branded cancer medications remain unchanged, ...

India's drug regulator DCGI cancels the import registration of FatX, a cosmetic product marketed with unauthorized ...

The FDA has cautioned Amgen about a promotional video for Vectibix, its colorectal cancer drug, which allegedly ...

Cipla targets a first wave launch of its Keytruda biosimilar QL2107 in the US after patent expiry in 2029, with expectations ...

Eli Lilly reveals significant leadership transitions as Patrik Jonsson announces retirement and Ilya Yuffa steps into the ...

Cipla's bispecific ADC rolditamig deruxtecan demonstrates a remarkable 71% reduction in disease progression for late-stage ...

China's drug regulator has approved Bayer's blood thinner Asundexian, promising a breakthrough in stroke prevention amid ...

Artiva Biotherapeutics has decided to suspend the development of its experimental cell therapy AlloNK, following two patient ...

Hengrui Pharmaceuticals, China's leading drugmaker, reported an impressive 88.9% increase in net profit for Q3 2026, driven ...